Cresco Labs (CRLBF) Cash from Investing Activities (2019 - 2026)
Cresco Labs (CRLBF) posted Cash from Investing Activities of $467000.0 for Q1 2026, up 103.53% on a QoQ basis from -$13.2 million in Q4 2025, and up 181.33% year-over-year from $166000.0 in Q1 2025.
Cresco Labs (CRLBF) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Cresco Labs' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $467000.0 for Q1 2026.
- Quarterly Cash from Investing Activities rose 181.33% year-over-year to $467000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.4 million (down 520.92% YoY) and the FY2025 annual result came in at -$40.7 million, down 61.34% from the prior year.
- Cash from Investing Activities was $467000.0 for Q1 2026 at Cresco Labs, up from -$13.2 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $23.5 million in Q3 2022 and bottomed at -$21.5 million in Q2 2025.
- A 5-year average of -$4.4 million and a median of -$6.1 million in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2025 — Cash from Investing Activities tumbled 339.5% — and 2026, when it jumped 181.33%.
- Cresco Labs' Cash from Investing Activities stood at -$12.5 million in 2022, then jumped by 120.95% to $2.6 million in 2023, then tumbled by 215.48% to -$3.0 million in 2024, then tumbled by 339.5% to -$13.2 million in 2025, then surged by 103.53% to $467000.0 in 2026.
- Business Quant data shows CRLBF's Cash from Investing Activities at $467000.0 in Q1 2026, -$13.2 million in Q4 2025, and -$6.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Cresco Labs | 245.85 Mn | 182.28 Mn | 75.45 Mn | 467,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 467,000.00 |
| Mar 31, 2026 | 467,000.00 |
| Dec 31, 2025 | -13.24 Mn |
| Dec 31, 2025 | -13.24 Mn |
| Sep 30, 2025 | -6.12 Mn |
| Sep 30, 2025 | -6.12 Mn |
| Jun 30, 2025 | -21.50 Mn |
| Jun 30, 2025 | -21.50 Mn |
| Mar 31, 2025 | 166,000.00 |
| Mar 31, 2025 | 166,000.00 |
| Dec 31, 2024 | -3.01 Mn |
| Dec 31, 2024 | -3.01 Mn |
| Sep 30, 2024 | -6.27 Mn |
| Sep 30, 2024 | -6.27 Mn |
| Dec 31, 2023 | 2.61 Mn |
| Dec 31, 2023 | 2.61 Mn |
| Sep 30, 2023 | -12.48 Mn |
| Sep 30, 2023 | -12.48 Mn |
| Dec 31, 2022 | -12.45 Mn |
| Dec 31, 2022 | -12.45 Mn |